Royal Bank Of Canada Lowers Exelixis (NASDAQ:EXEL) Price Target to $43.00

Exelixis (NASDAQ:EXEL) had its target price dropped by equities research analysts at Royal Bank Of Canada from $46.00 to $43.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 5.55% from the stock’s current price.

EXEL has been the topic of several other reports. Guggenheim downgraded shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. Bank of America downgraded shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price objective for the company. in a research report on Monday, January 5th. Citigroup lowered shares of Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. Stifel Nicolaus upped their target price on shares of Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $46.94.

Exelixis Trading Down 0.7%

Shares of Exelixis stock opened at $40.74 on Monday. The stock’s fifty day simple moving average is $43.87 and its 200 day simple moving average is $41.52. The company has a market capitalization of $10.58 billion, a PE ratio of 14.71, a PEG ratio of 0.92 and a beta of 0.41. Exelixis has a 12 month low of $32.38 and a 12 month high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.20. The company had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.55 earnings per share. Analysts predict that Exelixis will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In related news, EVP Dana Aftab sold 47,918 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the completion of the transaction, the executive vice president directly owned 616,106 shares of the company’s stock, valued at approximately $27,416,717. This represents a 7.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 67,814 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total value of $2,951,265.28. Following the completion of the transaction, the executive vice president owned 381,908 shares of the company’s stock, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 362,849 shares of company stock valued at $15,917,463 in the last ninety days. Insiders own 2.85% of the company’s stock.

Institutional Trading of Exelixis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after acquiring an additional 19,407 shares during the period. Goldman Sachs Group Inc. lifted its stake in Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after purchasing an additional 68,133 shares during the last quarter. Focus Partners Wealth grew its holdings in Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. grew its holdings in Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares during the period. Finally, Sivia Capital Partners LLC increased its position in Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after buying an additional 2,764 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks published a positive takecalling EXEL a “Top Value Stock for the Long-Term,” which supports a longer-term, value-oriented bull case for investors focused on valuation and cash flow. Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Morgan Stanley reiterated a Hold rating and kept its $49 price target, noting that while Welireg competition tempers RCC upside, the embedded cabozantinib franchise still provides support — a mixed view that keeps sentiment neutral. Exelixis: Welireg Competition Tempers RCC Upside but Embedded Cabozantinib Franchise Supports Hold Rating
• Neutral Sentiment: Benzinga and other roundups compiling multiple analyst projections provide a range of views (some bullish on long-term value, others cautious), meaning consensus remains mixed and investors should focus on which revenue scenarios play out. Forecasting The Future: 11 Analyst Projections For Exelixis
• Neutral Sentiment: Reported short-interest items show zero shares or inconsistent data (likely a reporting/data error), so there’s no clear short-squeeze signal to factor into near-term price action. (Market-impact: negligible until cleaned up.)
• Negative Sentiment: Royal Bank of Canada cut its price target to $43 and set a “sector perform” rating, signaling reduced upside expectations and likely contributing to downward pressure on the stock. Exelixis (NASDAQ:EXEL) Price Target Lowered to $43.00 at Royal Bank Of Canada
• Negative Sentiment: An investing.com item notes EXEL stock fell after a Merck trial produced stronger results versus competing approaches — competitive clinical data can reduce Exelixis’ market share and near-term growth prospects in relevant indications. Exelixis stock falls after rival Merck trial shows better results
• Negative Sentiment: Stifel reiterated a Hold rating, explicitly flagging emerging belzutifan competition and uncertain cabozantinib revenue visibility — commentary that reinforces cautious analyst positioning. Hold Rating on Exelixis Amid Emerging Belzutifan Competition and Uncertain Cabo Revenue Visibility
• Negative Sentiment: Wall Street Zen lowered its stock rating, another data point adding to negative near-term sentiment from some retail/independent research outlets. Exelixis (NASDAQ:EXEL) Stock Rating Lowered by Wall Street Zen

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.